Renalys Pharma is Introduced to Bring Groundbreaking Medicines to Patients in Japan and Various Asian Countries

Catalys Pacific and SR One, two significant life science investment firms with a presence across the Pacific and Atlantic, have jointly announced the formation of Renalys Pharma, Inc. This clinical-stage biopharmaceutical company is dedicated to developing treatments for individuals with renal disease, particularly focusing on Japan and selected Asian countries.

Renalys Pharma is committed to advancing sparsentan, an investigational dual-acting treatment developed by Travere Therapeutics, for patients with IgA nephropathy in Japan and specific Asian countries. Sparsentan, known in the US as FILSPARI®, functions as a dual endothelin and angiotensin receptor antagonist, offering a distinctive approach to IgA nephropathy treatment. Preclinical data indicates its efficacy in reducing proteinuria, protecting podocytes, and impeding the progression of kidney disease.

After successful consultations with Japan's Pharmaceuticals and Medical Devices Agency (PMDA), Renalys Pharma plans to initiate an open-label registrational study of sparsentan in Japan in Q2 2024. Leveraging global pivotal studies conducted earlier, the company aims to support potential sparsentan approval in Japan. Anticipated results from the study's UP/C endpoint in the second half of 2025 will contribute to the submission for PMDA approval. Sparsentan, as a non-immunosuppressive therapeutic, holds promise in safeguarding kidney function for a significant patient population.

Under the leadership of CEO BT Slingsby, Renalys Pharma emphasizes the importance of global collaboration in biopharma, aiming to forge cross-sectional partnerships and leverage new technologies to improve the lives of those with renal disease. The company adopts a patient-first approach, striving to offer comprehensive support for patients to lead fulfilling lives.

Supported by venture capital leaders Catalys Pacific and SR One, Renalys Pharma combines the expertise of both firms to advance renal disease treatments. The company has attracted top talent in renal drug development and commercialization, primarily from former executives of Kyowa Kirin, known for launching groundbreaking renal therapies.

Catalys Pacific, with a history of building transpacific life sciences companies, has contributed to the establishment of Renalys Pharma. The collaboration between Renalys Pharma, Catalys Pacific, and SR One reflects the global nature of biopharmaceutical cooperation. With end-to-end support from research to commercialization, Renalys Pharma is well-positioned to accelerate the development of innovative renal disease therapies. This international collaboration underscores the boundary-free essence of transformative scientific endeavors.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!